Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Ihab Kamel to Chemoembolization, Therapeutic

This is a "connection" page, showing publications Ihab Kamel has written about Chemoembolization, Therapeutic.

 
Connection Strength
 
 
 
12.817
 
  1. Zandieh G, Yazdaninia I, Afyouni S, Shaghaghi M, Borhani A, Mohseni A, Shaghaghi S, Liddell R, Kamel IR. Spectrum of Imaging Findings and Complications After Hepatic Transarterial Chemoembolization for Liver Tumors. J Comput Assist Tomogr. 2024 Sep-Oct 01; 48(5):701-712.
    View in: PubMed
    Score: 0.814
  2. Hazhirkarzar B, Shaghaghi M, Baghdadi A, Ghadimi M, Ghasabeh MA, Wu Q, Tang H, Khoshpouri P, Ameli S, Habibabadi RR, Motaghi M, Meyer CF, Kamel IR. Can Posttransarterial Chemoembolization Volumetric Oil Deposition on Computed Tomography Predict Treatment Response on Magnetic Resonance Imaging in Leiomyosarcoma Metastases to the Liver? J Comput Assist Tomogr. 2022 May-Jun 01; 46(3):327-332.
    View in: PubMed
    Score: 0.709
  3. Hazhirkarzar B, Tang H, Ghadimi M, Baghdadi A, Motaghi M, Wu Q, Shaghaghi M, Kamel I. Predicting early necrosis of colorectal liver metastases using volumetric enhancement on baseline MRI and oil deposition on post-cTACE unenhanced CT. Abdom Radiol (NY). 2021 10; 46(10):4610-4618.
    View in: PubMed
    Score: 0.668
  4. Shaghaghi M, AliyariG Hasabeh M, Ameli S, Ghadimi M, Hazhirkarzar B, Rezvani Habibabadi R, Tang H, Khoshpouri P, Wu Q, Pandey A, Pandey P, Baghdadi A, Kamel IR. Role of tumor margin and ADC change in defining the need for additional treatments after the first TACE in patients with unresectable HCC. Eur J Radiol. 2020 Dec; 133:109389.
    View in: PubMed
    Score: 0.642
  5. Shaghaghi M, Aliyari Ghasabeh M, Ameli S, Ghadimi M, Hazhirkarzar B, Rezvani Habibabadi R, Khoshpouri P, Pandey A, Pandey P, Kamel IR. Post-TACE changes in ADC histogram predict overall and transplant-free survival in patients with well-defined HCC: a retrospective cohort with up to 10 years follow-up. Eur Radiol. 2021 Mar; 31(3):1378-1390.
    View in: PubMed
    Score: 0.635
  6. Ameli S, Shaghaghi M, Ghasabeh MA, Pandey P, Hazhirkarzar B, Habibabadi RR, Ghadimi M, Khoshpouri P, Pandey A, Kamel IR. Does the change in volumetric functional MR metrics post-TACE predict histopathologic grading of hepatocellular carcinoma? Eur Radiol. 2020 Dec; 30(12):6709-6720.
    View in: PubMed
    Score: 0.629
  7. Luo Y, Ameli S, Pandey A, Khoshpouri P, Ghasabeh MA, Pandey P, Li Z, Hu D, Kamel IR. Semi-quantitative visual assessment of hepatic tumor burden can reliably predict survival in neuroendocrine liver metastases treated with transarterial chemoembolization. Eur Radiol. 2019 Nov; 29(11):5804-5812.
    View in: PubMed
    Score: 0.579
  8. Luo Y, Pandey A, Ghasabeh MA, Pandey P, Varzaneh FN, Zarghampour M, Khoshpouri P, Ameli S, Li Z, Hu D, Kamel IR. Prognostic value of baseline volumetric multiparametric MR imaging in neuroendocrine liver metastases treated with transarterial chemoembolization. Eur Radiol. 2019 Oct; 29(10):5160-5171.
    View in: PubMed
    Score: 0.573
  9. Pandey A, Pandey P, Ghasabeh MA, Zarghampour M, Khoshpouri P, Ameli S, Luo Y, Kamel IR. Baseline Volumetric Multiparametric MRI: Can It Be Used to Predict Survival in Patients with Unresectable Intrahepatic Cholangiocarcinoma Undergoing Transcatheter Arterial Chemoembolization? Radiology. 2018 12; 289(3):843-853.
    View in: PubMed
    Score: 0.551
  10. Pandey A, Pandey P, Aliyari Ghasabeh M, Najmi Varzaneh F, Shao N, Khoshpouri P, Zarghampour M, Fouladi DF, Liddell R, Kamel IR. Unresectable Intrahepatic Cholangiocarcinoma: Multiparametric MR Imaging to Predict Patient Survival. Radiology. 2018 Jul; 288(1):109-117.
    View in: PubMed
    Score: 0.536
  11. Najmi Varzaneh F, Pandey A, Aliyari Ghasabeh M, Shao N, Khoshpouri P, Pandey P, Zarghampour M, Fouladi D, Liddell R, Anders RA, Kamel IR. Prediction of post-TACE necrosis of hepatocellular carcinoma usingvolumetric enhancement on MRI and volumetric oil deposition on CT, with pathological correlation. Eur Radiol. 2018 Jul; 28(7):3032-3040.
    View in: PubMed
    Score: 0.530
  12. Chu LC, Pozzessere C, Corona-Villalobos CP, Castaños S, Rastegar N, Halappa V, Bonekamp S, Emurano E, Kamel IR. Evaluation of Hepatocellular Carcinoma Tumor Response After Transcatheter Arterial Chemoembolization Using Gadobenate Dimeglumine-Enhanced Liver Magnetic Resonance. J Comput Assist Tomogr. 2016 Nov/Dec; 40(6):856-862.
    View in: PubMed
    Score: 0.486
  13. Corona-Villalobos CP, Kamel IR. Functional volumetric MRI in assessing treatment response to intra-arterial therapy of primary and secondary liver tumors. J Comput Assist Tomogr. 2014 Jul-Aug; 38(4):513-7.
    View in: PubMed
    Score: 0.414
  14. Bonekamp D, Bonekamp S, Halappa VG, Geschwind JF, Eng J, Corona-Villalobos CP, Pawlik TM, Kamel IR. Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma. Eur J Radiol. 2014 Mar; 83(3):487-96.
    View in: PubMed
    Score: 0.397
  15. Bonekamp S, Li Z, Geschwind JF, Halappa VG, Corona-Villalobos CP, Reyes D, Pawlik TM, Bonekamp D, Eng J, Kamel IR. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. Identification and validation of volumetric functional response criteria. Radiology. 2013 Aug; 268(2):420-30.
    View in: PubMed
    Score: 0.381
  16. Bonekamp S, Halappa VG, Geschwind JF, Li Z, Corona-Villalobos CP, Reyes D, Bhagat N, Cosgrove DP, Pawlik TM, Mezey E, Eng J, Kamel IR. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy. Radiology. 2013 Aug; 268(2):431-9.
    View in: PubMed
    Score: 0.381
  17. Gowdra Halappa V, Corona-Villalobos CP, Bonekamp S, Li Z, Reyes D, Cosgrove D, Pawlik TM, Diaz LA, Bhagat N, Eng J, Geschwind JF, Kamel IR. Neuroendocrine liver metastasis treated by using intraarterial therapy: volumetric functional imaging biomarkers of early tumor response and survival. Radiology. 2013 Feb; 266(2):502-13.
    View in: PubMed
    Score: 0.370
  18. Halappa VG, Bonekamp S, Corona-Villalobos CP, Li Z, Mensa M, Reyes D, Eng J, Bhagat N, Pawlik TM, Geschwind JF, Kamel IR. Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response. Radiology. 2012 Jul; 264(1):285-94.
    View in: PubMed
    Score: 0.357
  19. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology. 2009 Feb; 250(2):466-73.
    View in: PubMed
    Score: 0.284
  20. El-Khouli RH, Geschwind JF, Bluemke DA, Kamel IR. Solitary fibrous tumor of the liver: magnetic resonance imaging evaluation and treatment with transarterial chemoembolization. J Comput Assist Tomogr. 2008 Sep-Oct; 32(5):769-71.
    View in: PubMed
    Score: 0.276
  21. Buijs M, Vossen JA, Hong K, Georgiades CS, Geschwind JF, Kamel IR. Chemoembolization of hepatic metastases from ocular melanoma: assessment of response with contrast-enhanced and diffusion-weighted MRI. AJR Am J Roentgenol. 2008 Jul; 191(1):285-9.
    View in: PubMed
    Score: 0.273
  22. Liapi E, Geschwind JF, Vossen JA, Buijs M, Georgiades CS, Bluemke DA, Kamel IR. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol. 2008 Jan; 190(1):67-73.
    View in: PubMed
    Score: 0.264
  23. Vossen JA, Buijs M, Kamel IR. Assessment of tumor response on MR imaging after locoregional therapy. Tech Vasc Interv Radiol. 2006 Sep; 9(3):125-32.
    View in: PubMed
    Score: 0.240
  24. Kamel IR, Bluemke DA, Eng J, Liapi E, Messersmith W, Reyes DK, Geschwind JF. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol. 2006 Mar; 17(3):505-12.
    View in: PubMed
    Score: 0.232
  25. Kamel IR, Bluemke DA, Ramsey D, Abusedera M, Torbenson M, Eng J, Szarf G, Geschwind JF. Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol. 2003 Sep; 181(3):708-10.
    View in: PubMed
    Score: 0.195
  26. Fouladi DF, Zarghampour M, Pandey P, Pandey A, Varzaneh FN, Ghasabeh MA, Khoshpouri P, Kamel IR. Baseline 3D-ADC outperforms 2D-ADC in predicting response to treatment in patients with colorectal liver metastases. Eur Radiol. 2020 Jan; 30(1):291-300.
    View in: PubMed
    Score: 0.146
  27. Cosgrove DP, Reyes DK, Pawlik TM, Feng AL, Kamel IR, Geschwind JF. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results. Radiology. 2015 Nov; 277(2):594-603.
    View in: PubMed
    Score: 0.110
  28. Chapiro J, Wood LD, Lin M, Duran R, Cornish T, Lesage D, Charu V, Schernthaner R, Wang Z, Tacher V, Savic LJ, Kamel IR, Geschwind JF. Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis. Radiology. 2014 Dec; 273(3):746-58.
    View in: PubMed
    Score: 0.104
  29. Dodson RM, Firoozmand A, Hyder O, Tacher V, Cosgrove DP, Bhagat N, Herman JM, Wolfgang CL, Geschwind JF, Kamel IR, Pawlik TM. Impact of sarcopenia on outcomes following intra-arterial therapy of hepatic malignancies. J Gastrointest Surg. 2013 Dec; 17(12):2123-32.
    View in: PubMed
    Score: 0.098
  30. Buijs M, Reyes DK, Pawlik TM, Blackford AL, Salem R, Messersmith WA, Weekes CD, Mulcahy M, Kamel IR, Geschwind JF. Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer. 2013 Mar 01; 119(5):1042-9.
    View in: PubMed
    Score: 0.092
  31. Georgiades C, Geschwind JF, Harrison N, Hines-Peralta A, Liapi E, Hong K, Wu Z, Kamel I, Frangakis C. Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? Radiology. 2012 Oct; 265(1):115-23.
    View in: PubMed
    Score: 0.091
  32. Bhagat N, Reyes DK, Lin M, Kamel I, Pawlik TM, Frangakis C, Geschwind JF. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol. 2013 Apr; 36(2):449-59.
    View in: PubMed
    Score: 0.090
  33. Peng PD, Hyder O, Bloomston M, Marques H, Corona-Villalobos C, Dixon E, Pulitano C, Hirose K, Schulick RD, Barroso E, Aldrighetti L, Choti M, Shen F, Kamel I, Geschwind JF, Pawlik TM. Sequential intra-arterial therapy and portal vein embolization is feasible and safe in patients with advanced hepatic malignancies. HPB (Oxford). 2012 Aug; 14(8):523-31.
    View in: PubMed
    Score: 0.089
  34. Kneuertz PJ, Demirjian A, Firoozmand A, Corona-Villalobos C, Bhagat N, Herman J, Cameron A, Gurakar A, Cosgrove D, Choti MA, Geschwind JF, Kamel IR, Pawlik TM. Diffuse infiltrative hepatocellular carcinoma: assessment of presentation, treatment, and outcomes. Ann Surg Oncol. 2012 Sep; 19(9):2897-907.
    View in: PubMed
    Score: 0.089
  35. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol. 2011 Oct 20; 29(30):3960-7.
    View in: PubMed
    Score: 0.085
  36. Reyes DK, Vossen JA, Kamel IR, Azad NS, Wahlin TA, Torbenson MS, Choti MA, Geschwind JF. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J. 2009 Nov-Dec; 15(6):526-32.
    View in: PubMed
    Score: 0.075
  37. Hong K, McBride JD, Georgiades CS, Reyes DK, Herman JM, Kamel IR, Geschwind JF. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol. 2009 Mar; 20(3):360-7.
    View in: PubMed
    Score: 0.071
  38. Vossen JA, Kamel IR, Buijs M, Liapi E, Georgiades CS, Hong K, Geschwind JF. Role of functional magnetic resonance imaging in assessing metastatic leiomyosarcoma response to chemoembolization. J Comput Assist Tomogr. 2008 May-Jun; 32(3):347-52.
    View in: PubMed
    Score: 0.067
  39. Buijs M, Kamel IR, Vossen JA, Georgiades CS, Hong K, Geschwind JF. Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging. J Vasc Interv Radiol. 2007 Aug; 18(8):957-63.
    View in: PubMed
    Score: 0.064
  40. Burger I, Hong K, Schulick R, Georgiades C, Thuluvath P, Choti M, Kamel I, Geschwind JF. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol. 2005 Mar; 16(3):353-61.
    View in: PubMed
    Score: 0.054
  41. Kamel IR, Fishman EK. Recent advances in CT imaging of liver metastases. Cancer J. 2004 Mar-Apr; 10(2):104-20.
    View in: PubMed
    Score: 0.051
  42. Mayo SC, Herman JM, Cosgrove D, Bhagat N, Kamel I, Geschwind JF, Pawlik TM. Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies. J Am Coll Surg. 2013 Jan; 216(1):123-34.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)